ABP 501

adalimumab biosimilar · Amgen

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for ABP 501, covering 2016-12-13 to 2024-02-09. Get the full timeline:

Most recent: Clinical Trial Update: A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis [Phase 3]

See pricing